-
2024-510616-73-00
5
2020-12-16
newly diagnosed WHO grade 2 or 3 glioma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2024-514962-38-00
1
2020-08-25
Solid Tumors
-
2024-512654-19-00
5
2020-03-06
Sickle Cell Disease
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-512321-84-00
5
2019-10-02
Patients after HSCT suffering from new or reactivated CMV or EBV or Ad
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-513526-27-00
4
2018-02-23
secondary or quaternary peritonitis
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2025-521970-33-00
5
2025-12-19
Pulmonary Arterial Hypertension (PAH)
-
2024-511452-40-00
10
2025-09-12
Oncology - Glioblastoma (GBM)
-
2024-512914-16-00
5
2025-09-12
Relapsing-remitting Multiple Sclerosis
-
2024-518998-33-00
5
2025-07-23
Ulcerative Colitis
-
2024-519095-66-00
5
2025-07-23
Kidney Transplant Recipients with Late Antibody-Mediated Rejection
-
2022-503001-38-01
5
2025-07-08
HR-positive HER-2- negative Breast Cancer
-
2024-514064-17-00
3
2025-05-23
Pulmonary Arterial Hypertension
-
2024-513738-39-00
9
2025-03-18
IDH1-mutant Glioma
-
2023-505394-32-00
5
2025-02-06
chronic graft versus host disease
-
2024-511482-11-00
5
2024-11-20
Dry Age-Related Macular Degeneration (Dry AMD)